A detailed history of High Tower Advisors, LLC transactions in Bio Atla, Inc. stock. As of the latest transaction made, High Tower Advisors, LLC holds 13,000 shares of BCAB stock, worth $22,360. This represents 0.0% of its overall portfolio holdings.

Number of Shares
13,000
Previous 13,500 3.7%
Holding current value
$22,360
Previous $18,000 22.22%
% of portfolio
0.0%
Previous 0.0%

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$1.17 - $2.05 $585 - $1,025
-500 Reduced 3.7%
13,000 $22,000
Q2 2024

Aug 13, 2024

BUY
$1.37 - $3.92 $685 - $1,960
500 Added 3.85%
13,500 $18,000
Q1 2024

May 06, 2024

SELL
$1.88 - $3.46 $752 - $1,384
-400 Reduced 2.99%
13,000 $44,000
Q4 2023

Feb 12, 2024

BUY
$1.27 - $3.18 $508 - $1,272
400 Added 3.08%
13,400 $32,000
Q2 2022

Aug 10, 2022

BUY
$2.13 - $5.38 $27,690 - $69,940
13,000 New
13,000 $37,000

Others Institutions Holding BCAB

About BioAtla, Inc.


  • Ticker BCAB
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 36,304,100
  • Market Cap $62.4M
  • Description
  • BioAtla, Inc., a clinical stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its lead product candidate is BA3011, a conditionally active biologic (CAB) antibody-drug conjugate (ADC) for soft tissue and bone sarcoma tumors, non-small cell lung cancer (NSCLC), and ...
More about BCAB
Track This Portfolio

Track High Tower Advisors, LLC Portfolio

Follow High Tower Advisors, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of High Tower Advisors, LLC, based on Form 13F filings with the SEC.

News

Stay updated on High Tower Advisors, LLC with notifications on news.